MYOS Corp Receives New US Patent for Human and Animal Musculoskeletal Health Treatment
MYOS Corp, a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today the issuance of United States Patent # 10,835,576 B2 from the United States Patent and Trademark Office (USPTO) on November 17, 2020 claiming a method of increasing muscle mass in those suffering from degenerating diseases associated with wasting of skeletal muscle. This new method of treatment patent significantly enhances MYOS’ existing intellectual property portfolio, enabling MYOS to protect its advanced technologies for the development of innovative nutrition products to address musculoskeletal health.
Joseph Mannello, CEO of MYOS, commented, “I am delighted that the USPTO has issued MYOS its most recent patent. I am committed to building a world class company that is focused on redefining muscle health. In order to meet that goal, MYOS has invested extensively in research and development over the last several years. Earlier this year, very promising results were published on veterinary and human clinical studies that we sponsored at Kansas State University and the University of California, Berkeley. I believe this new patent will prove vital as we capitalize on our investments in R&D, enabling us to deliver the maximum value to our shareholders.”
The new patent relates to a drinkable consumer health product shown to increase muscle mass in individuals with a muscle degenerating disease. Researchers at the University of California, Berkeley reported that in a randomized, double blind, placebo-controlled human clinical trial involving 60-75 year old men and women, subjects who consumed Fortetropin experienced an increase of ~18 percent in the rate of muscle protein synthesis relative to subjects who received a macronutrient-matched placebo. Fortetropin is a fertilized avian egg yolk-based product that is manufactured using advanced, proprietary technologies and is owned by MYOS Corp.
In addition, results published earlier this year from a randomized, double blind, placebo-controlled veterinary clinical trial involving Fortetropin that was conducted at Kansas State University demonstrated that dogs that received Fortetropin following a common orthopedic surgical procedure known as TPLO surgery experienced reduced muscle atrophy and improved recovery relative to dogs that received a macronutrient-matched placebo.
MYOS initiated a human clinical trial at McMaster University earlier this year following the completion of the aforementioned study in order to address the growing Recovery & Rehabilitation Market.
“This is a very exciting time for MYOS as we just completed a reverse merger transaction and have transitioned from a public company to a private company. Going forward, we plan to launch many novel nutrition products in different formats to address muscle health. The invention that this patent protects will enable us to diversify our product offerings going forward and maximize returns to our shareholders,” added Mannello.